Glimisave M 3 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to release insulin, thereby enhancing insulin secretion and improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The synergistic effect of these two agents helps in achieving better blood glucose regulation compared to monotherapy. Glimisave M 3 Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent do not provide adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, particularly due to Glimepiride. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis, severe renal dysfunction, and hypersensitivity to any component. This medication should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.